Role of teriparatide in treatment of glucocorticoid-induced osteoporosis

References

• van StaaTPLeufkensHGAbenhaimLBegaudBZhangBCooperCUse of oral corticosteroids in the United KingdomQJM200093210511110700481
   PubMed Web of Science ®Google Scholar
• RogerLSerious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritisAm J Med19959966926947503098
   PubMed Web of Science ®Google Scholar
• LukertBPRaiszLGGlucocorticoid-induced osteoporosis: Pathogenesis and managementAnn Intern Med199011253523642407167
   PubMed Web of Science ®Google Scholar
• van StaaTPLeufkensHGAbenhaimLZhangBCooperCUse of oral corticosteroids and risk of fracturesJ Bone Miner Res2000156993100010841167
   PubMed Web of Science ®Google Scholar
• van StaaTPLeufkensHGCooperCThe epidemiology of corticosteroid-induced osteoporosis: A meta-analysisOsteoporos Int2002131077778712378366
   PubMed Web of Science ®Google Scholar
• AdachiJDBensenWGBianchiFCividinoAPillersdorfSSebaldtRJVitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year followupJ Rheumatol199623699510008782129
   PubMed Web of Science ®Google Scholar
• IpMLamKYamLKungANgMDecreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroidsChest19941056172217278205866
   PubMed Web of Science ®Google Scholar
• ToogoodJHBaskervilleJCMarkovAEBone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthmaJ Allergy Clin Immunol19959621571667636052
   PubMed Web of Science ®Google Scholar
• van StaaTPLeufkensHGCooperCUse of inhaled corticosteroids and risk of fracturesJ Bone Miner Res200116358158811277277
   PubMed Web of Science ®Google Scholar
• van StaaTPBishopNLeufkensHGCooperCAre inhaled corticosteroids associated with an increased risk of fracture in children?Osteoporos Int2004151078579114985948
   PubMed Web of Science ®Google Scholar
• CanalisEBilezikianJPAngeliAGiustinaAPerspectives on glucocorticoid-induced osteoporosisBone200434459359815050888
   PubMed Web of Science ®Google Scholar
• CanalisEMechanisms of glucocorticoid action in boneCurr Osteoporos Rep2005339810216131429
   PubMedGoogle Scholar
• O’BrienCAJiaDPlotkinLIGlucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strengthEndocrinology200414541835184114691012
   PubMed Web of Science ®Google Scholar
• WuZBucherNLFarmerSRInduction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoidsMol Cell Biol1996168412841368754811
   PubMed Web of Science ®Google Scholar
• WeinsteinRSJilkaRLParfittAMManolagasSCInhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on boneJ Clin Invest199810222742829664068
   PubMed Web of Science ®Google Scholar
• WeinsteinRSGlucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularityBone201046356457019591965
   PubMed Web of Science ®Google Scholar
• LaneNEYaoWBaloochMGlucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient miceJ Bone Miner Res200621346647616491295
   PubMed Web of Science ®Google Scholar
• MurrayTMRaoLGDivietiPParathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligandsEndocr Rev20052617811315689574
   PubMed Web of Science ®Google Scholar
• DempsterDWCosmanFParisienMShenVLindsayRAnabolic actions of parathyroid hormone on boneEndocr Rev19931466907098119233
   PubMed Web of Science ®Google Scholar
• GiustinaAVeldhuisJDPathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the humanEndocr Rev19981967177979861545
   PubMed Web of Science ®Google Scholar
• ZhaoGMonier-FaugereMCLangubMCTargeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: Increased trabecular bone volume without increased osteoblast proliferationEndocrinology200014172674268210875273
   PubMed Web of Science ®Google Scholar
• CanalisEEconomidesANGazzerroEBone morphogenetic proteins, their antagonists, and the skeletonEndocr Rev200324221823512700180
   PubMed Web of Science ®Google Scholar
• KrishnanVBryantHUMacdougaldOARegulation of bone mass by Wnt signalingJ Clin Invest200611651202120916670761
   PubMed Web of Science ®Google Scholar
• BellidoTAliAAGubrijIChronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesisEndocrinology2005146114577458316081646
   PubMed Web of Science ®Google Scholar
• BenhamouCLEffects of osteoporosis medications on bone qualityJoint Bone Spine200774394717196423
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone 1–34 on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
   PubMed Web of Science ®Google Scholar
• MarcusRWangOSatterwhiteJMitlakBThe skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosisJ Bone Miner Res2003181182312510801
   PubMed Web of Science ®Google Scholar
• NevittMChenPKielDPReduced risk of back pain following teriparatide treatment: A meta-analysisOsteoporos Int200617227328016142502
   PubMed Web of Science ®Google Scholar
• ChenPMillerPDDelmasPMisurskiDAKregeJHChanges in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women in osteoporosisJ Bone Miner Res200621111785179017002571
   PubMed Web of Science ®Google Scholar
• LauANAliSHSawkaAMImprovement in health-related quality of life in osteoporosis patients treated with teriparatideBMC Musculoskelet Disord2008915118990249
   PubMed Web of Science ®Google Scholar
• CompstonJUS and UK guidelines for glucocorticoid-induced osteoporosis: Similarities and differencesCurr Rheumatol Rep200461666914713404
   PubMedGoogle Scholar
• AbadieECDevogealerJPRingeJDRecommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: Updated recommendations from the Group for the Respect of Ethics and Excellence in ScienceSemin Arthritis Rheum20053511416084217
   PubMed Web of Science ®Google Scholar
• LaneNESanchezSModinGWGenantHKPieriniEArnaudCDParathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trialJ Clin Invest19981028162716339788977
   PubMed Web of Science ®Google Scholar
• LaneNESanchezSModinGWGenantHKPieriniEArnaudCDBone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trialJ Bone Miner Res200015594495110804025
   PubMed Web of Science ®Google Scholar
• RehmanQLangTFArnaudCDModinGWLaneNEDaily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocortico-idinduced osteoporosisOsteoporos Int2003141778112577188
   PubMed Web of Science ®Google Scholar
• SaagKGZanchettaJRDevogelaerJPEffects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trialArthritis Rheum200960113346335519877063
   PubMed Web of Science ®Google Scholar
• DevogelaerJPAdlerRARecknorCBaseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosisJ Rheumatol201037114114819918047
   PubMed Web of Science ®Google Scholar
• EastellRChenPSaagKGBone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronateBone201046492993420060078
   PubMed Web of Science ®Google Scholar
• MillerPDSafety of parathyroid hormone for treatment of osteoporosisCurr Osteoporos Rep20086121618430395
   PubMedGoogle Scholar
• GiustiAHamdyNAPapapoulosSEAtypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studiesBone201047216918020493982
   PubMed Web of Science ®Google Scholar